Όλο το DSpace

Πλοήγηση ανά Συγγραφέα "Navarro-Sarabia, F."

Αποτελέσματα 1-4 από 4

    • Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis 

      Montes, A.; Perez-Pampin, E.; Narváez, J.; Cañete, J. D.; Navarro-Sarabia, F.; Moreira, V.; Fernández-Nebro, A.; Del Carmen Ordóñez, M.; De La Serna, A. R.; Magallares, B.; Vasilopoulos, Y.; Sarafidou, T.; Caliz, R.; Ferrer, M. A.; Joven, B.; Carreira, P.; Gómez-Reino, J. J.; Gonzalez, A. (2014)
      OBJECTIVES: We aimed to assess a functional polymorphism in FCGR2A H131R, for association with the treatment response to Fc-containing inhibitors of tumor necrosis factor (TNF). METHODS: A total of 429 biologic-naive ...

    • FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors 

      Montes, A.; Perez-Pampin, E.; Joven, B.; Carreira, P.; Fernandez-Nebro, A.; Ordonez, M. D.; Navarro-Sarabia, F.; Moreira, V.; Vasilopoulos, Y.; Sarafidou, T.; Caliz, R.; Ferrer, M. A.; Canete, J. D.; de la Serna, A. R.; Magallares, B.; Narvaez, J.; Gomez-Reino, J. J.; Gonzalez, A. (2015)
      Objectives: Reproducible association of a functional polymorphism in FCGR2A with response to a TNF inhibitor (TNFi) in patients with rheumatoid arthritis (RA) led us to explore other Fc gamma R functional polymorphisms. ...

    • REDUCED CLINICAL IMPROVEMENT IN RHEUMATOID ARTHRITIS PATIENTS SHOWING IGG1 ALLOTYPE -INFLIXIMAB INCOMPATIBILITY 

      Montes, A.; Perez-Pampin, E.; Navarro-Sarabia, F.; Moreira, V.; de la Serna, A. R.; Magallanes, B.; Vasilopoulos, Y.; Sarafidou, T.; Fernandez-Nebro, A.; Ordonez, M. D. C.; Narvaez, J.; Canete, J. D.; Isaacs, J.; Morgan, A.; Barton, A.; Wilson, A. G.; Gomez-Reino, J. J.; Gonzalez, A.; Bragggss (2013)

    • Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study 

      Montes, A.; Perez-Pampin, E.; Navarro-Sarabia, F.; Moreira, V.; de la Sema, A. R.; Magallares, B.; Vasilopoulos, Y.; Sarafidou, T.; Fernandez-Nebro, A.; Ordonez, M. D.; Narvaez, J.; Canete, J. D.; Marquez, A.; Pascual-Salcedo, D.; Joven, B.; Carreira, P.; Moreno-Ramos, M. J.; Caliz, R.; Ferrer, M. A.; Garcia-Portales, R.; Blanco, F. J.; Magro, C.; Raya, E.; Valor, L.; Alegre-Sancho, J. J.; Balsa, A.; Martin, J.; Plant, D.; Isaacs, J.; Morgan, A. W.; Barton, A.; Wilson, A. G.; Gomez-Reino, J. J.; Gonzalez, A.; Braggss (2015)
      Introduction: We have hypothesized that incompatibility between the G1m genotype of the patient and the G1m1 and G1m17 allotypes carried by infliximab (INX) and adalimumab (ADM) could decrease the efficacy of these anti-tumor ...